
    
      This study has 3 parts. Participants may only enroll in one part.

      Part A - Participants will receive LY2875358.

      Part B1 - Participants with non-small cell lung cancer (NSCLC) will receive LY2875358 and
      erlotinib.

      Part B2 - Participants with NSCLC will receive LY2875358 and gefitinib.

      Parts B1 and B2 were added per protocol amendment in January, 2013.
    
  